Clinical Trial Update: HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for gabapentin enacarbil (HORIZANT) in alcohol use disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder

Drugs mentioned

• Horizant (gabapentin enacarbil)

Snippet

Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Conditions: Alcohol Use Disorder | Phase 2 | Status: COMPLETED | Results posted: 2018-09-21